

Fuyo General Lease Co., Ltd.
President & Chief Executive Officer
Yasunori Tsujita
3-3-23, Kanda-Misaki-cho, Chiyoda-ku, Tokyo

CREWT Medical Systems, Inc.
President & Chief Executive Officer
Tetsuya Eguchi
TH1 Bldg. Iidabashi 3F,
3-11, Tsukudo-cho, Shinjuku-ku, Tokyo

Fuyo Lease and CREWT Medical Systems Enter Capital and Business Alliance

1. Fuyo Lease and CREWT Medical Systems have entered a Capital and Business Alliance Agreement, which includes underwriting a capital increase via third-party allotment, and financing and other support for sales of head-mounted perimeters.
2. CREWT Medical Systems is a business venture affiliated with the University of Tokyo. Its strength lies in the development of leading-edge medical devices, including development of the head-mounted perimeter “imo,” (hereinafter “imo”) which can perform speedy, less-fatiguing tests of the visual field that are essential for diagnosing glaucoma.

Fuyo General Lease Co., Ltd. (“Fuyo Lease”; Chiyoda-ku, Tokyo; Yasunori Tsujita, President & Chief Executive Officer) and CREWT Medical Systems, Inc. (“CREWT”; Shinjuku-ku, Tokyo; Tetsuya Eguchi, President & Chief Executive Officer) have entered a Capital and Business Alliance Agreement, whereby Fuyo Lease will underwrite a capital increase via third-party allotment by CREWT, and provide financial support for the sale of head-mounted perimeters developed by CREWT.

CREWT is a business venture affiliated with the University of Tokyo established in 2013. It is a developer of “imo,” the world’s first head-mounted perimeter, which is essential for diagnosing glaucoma; “imo” has been sold since December 2015.

“imo” was jointly developed by a group including the University of Tokyo Medical School Ophthalmology Course and the Kinki University Medical School Ophthalmology Course. It does not require a darkroom, its compact form and light weight make it portable, and it is able to examine both eyes at once. In addition to these features, it includes leading-edge functions such as automatic tracking correction during pupil examination, and a proprietary examination program with short measurement time.

Glaucoma is the leading cause of blindness in Japan, and according to a study by the Japan Glaucoma Society, 1 in 20 people aged 40 and over are affected by this disease. However, there are almost no noticeable symptoms until the loss of visual field progresses. By the time patients notice the symptoms, the disease has already reached an advanced stage. Therefore, promotion of early detection and treatment is a major challenge.

Meanwhile, the testing methods and length of time of existing glaucoma diagnosis place a large burden both on medical institutions and patients, and this is reported to be one of the obstacles to early detection and treatment of glaucoma. By promoting the adoption of “imo” that reduces the burden on both medical institutions and patients, Fuyo Lease and CREWT intends to promote early detection of glaucoma, and help to control the progression of symptoms by starting treatment early.

The third-party allotment conducted by CREWT was undertaken through venture capital in the past. However, this time, the third-party allotment will be underwritten by a business company, Fuyo Lease, for the first time. In addition to the financing, Fuyo Lease plans to support the spread of “imo” through leasing and various other financing plans.

Fuyo Lease and CREWT intend to contribute to the development and expansion of leading-edge medical devices by continuing to strengthen their alliance.

[CREWT’s head-mounted perimeter “imo”]



Direct inquiries to:

Yoshida / Saito Corporate Communications Div., Fuyo General Lease Co., Ltd.
Phone +81 (3) 5275 8891 URL <http://www.fgl.co.jp/eng/>

CREWT Medical Systems, Inc.
Email info@crewt.co.jp URL <https://www.crewt.co.jp>